Dimensional Fund Advisors LP Decreases Holdings in Karyopharm Therapeutics Inc (KPTI)

Dimensional Fund Advisors LP trimmed its holdings in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 1.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 319,042 shares of the company’s stock after selling 4,629 shares during the period. Dimensional Fund Advisors LP’s holdings in Karyopharm Therapeutics were worth $3,503,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Schwab Charles Investment Management Inc. lifted its stake in Karyopharm Therapeutics by 21.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 140,360 shares of the company’s stock valued at $1,542,000 after acquiring an additional 24,324 shares during the period. JPMorgan Chase & Co. lifted its stake in Karyopharm Therapeutics by 753.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock valued at $3,342,000 after acquiring an additional 271,208 shares during the period. Candriam Luxembourg S.C.A. lifted its stake in Karyopharm Therapeutics by 16.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock valued at $5,600,000 after acquiring an additional 72,000 shares during the period. Nationwide Fund Advisors lifted its stake in shares of Karyopharm Therapeutics by 396.0% in the 3rd quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock valued at $1,160,000 after purchasing an additional 84,362 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Karyopharm Therapeutics by 12.2% in the 2nd quarter. California State Teachers Retirement System now owns 59,844 shares of the company’s stock valued at $542,000 after purchasing an additional 6,500 shares during the period. Institutional investors and hedge funds own 58.02% of the company’s stock.

Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) opened at $11.20 on Tuesday. Karyopharm Therapeutics Inc has a 1-year low of $7.48 and a 1-year high of $14.63.

In other news, CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $10.09, for a total transaction of $100,900.00. Following the completion of the sale, the chief executive officer now owns 522,143 shares of the company’s stock, valued at $5,268,422.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Christopher Brett Primiano sold 27,042 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $10.28, for a total transaction of $277,991.76. Following the sale, the senior vice president now directly owns 11,381 shares of the company’s stock, valued at approximately $116,996.68. The disclosure for this sale can be found here. Insiders have sold 67,042 shares of company stock valued at $675,192 in the last ninety days. Insiders own 14.71% of the company’s stock.

Several research firms recently issued reports on KPTI. Royal Bank of Canada reiterated a “buy” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, October 18th. Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Zacks Investment Research cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $17.33.

TRADEMARK VIOLATION NOTICE: “Dimensional Fund Advisors LP Decreases Holdings in Karyopharm Therapeutics Inc (KPTI)” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/02/06/dimensional-fund-advisors-lp-decreases-holdings-in-karyopharm-therapeutics-inc-kpti.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply